WO2000073801A3 - Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation - Google Patents

Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation Download PDF

Info

Publication number
WO2000073801A3
WO2000073801A3 PCT/US2000/014749 US0014749W WO0073801A3 WO 2000073801 A3 WO2000073801 A3 WO 2000073801A3 US 0014749 W US0014749 W US 0014749W WO 0073801 A3 WO0073801 A3 WO 0073801A3
Authority
WO
WIPO (PCT)
Prior art keywords
associated antigens
molecules
cancer
cancer associated
peptides
Prior art date
Application number
PCT/US2000/014749
Other languages
English (en)
Other versions
WO2000073801A2 (fr
Inventor
Yuichi Obata
Original Assignee
Ludwig Inst Cancer Res
Yuichi Obata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Yuichi Obata filed Critical Ludwig Inst Cancer Res
Priority to EP00932804A priority Critical patent/EP1259812A2/fr
Priority to AU50478/00A priority patent/AU5047800A/en
Priority to JP2001500870A priority patent/JP2003518364A/ja
Priority to US09/979,932 priority patent/US7166573B1/en
Publication of WO2000073801A2 publication Critical patent/WO2000073801A2/fr
Publication of WO2000073801A3 publication Critical patent/WO2000073801A3/fr
Priority to US11/656,200 priority patent/US20070128655A1/en
Priority to US12/254,078 priority patent/US7879981B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Des antigènes associés au cancer ont été identifiés par le criblage d'anticorps autologues de banques d'acides nucléiques exprimés dans des cellules cancéreuses du sein, de la prostate et de l'estomac, au moyen du sérum immun de patients atteints d'un cancer. L'invention concerne des acides nucléiques et des polypeptides codés qui sont des antigènes associés au cancer exprimés chez des patients atteints d'un cancer. Plus spécialement, l'invention concerne, entre autres, des molécules isolées d'acide nucléique, des vecteurs d'expression renfermant ces molécules et des cellules hôtes dans lesquelles on a transfecté ces molécules. La présente invention concerne également des protéines et des peptides isolés, des anticorps de ces derniers, ainsi que des lymphocytes T cytotoxiques reconnaissant les protéines et les peptides. L'invention concerne en outre des fragments des éléments précités, dont des fragments fonctionnels et des variantes, ainsi que des kits contenant lesdites molécules. Les molécules de la présente invention peuvent être utilisées à des fins de diagnostic, de surveillance, de recherche ou de traitement des conditions caractérisées par l'expression d'un ou plusieurs antigènes associés au cancer.
PCT/US2000/014749 1999-05-28 2000-05-26 Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation WO2000073801A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP00932804A EP1259812A2 (fr) 1999-05-28 2000-05-26 Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
AU50478/00A AU5047800A (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor
JP2001500870A JP2003518364A (ja) 1999-05-28 2000-05-26 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
US09/979,932 US7166573B1 (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor
US11/656,200 US20070128655A1 (en) 1999-05-28 2007-01-22 Breast, gastric and prostate cancer associated antigens and uses therefor
US12/254,078 US7879981B2 (en) 1999-05-28 2008-10-20 Breast, gastric and prostate cancer associated antigens and uses therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13652699P 1999-05-28 1999-05-28
US60/136,526 1999-05-28
US15345499P 1999-09-10 1999-09-10
US60/153,454 1999-09-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09979932 A-371-Of-International 2000-05-26
US11/656,200 Division US20070128655A1 (en) 1999-05-28 2007-01-22 Breast, gastric and prostate cancer associated antigens and uses therefor

Publications (2)

Publication Number Publication Date
WO2000073801A2 WO2000073801A2 (fr) 2000-12-07
WO2000073801A3 true WO2000073801A3 (fr) 2002-09-12

Family

ID=26834386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014749 WO2000073801A2 (fr) 1999-05-28 2000-05-26 Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation

Country Status (4)

Country Link
EP (1) EP1259812A2 (fr)
JP (1) JP2003518364A (fr)
AU (1) AU5047800A (fr)
WO (1) WO2000073801A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6737040B1 (en) 1998-08-04 2004-05-18 Diadexus, Inc. Method and antibody for imaging breast cancer
US6730477B1 (en) 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
EP1006184A1 (fr) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag Protéines interagissant avec le récepteur de IGF-1, gènes codant pour ces protéines et leurs utilisations
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6262247B1 (en) * 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
EP1248800A2 (fr) 1999-11-30 2002-10-16 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
WO2001047959A2 (fr) * 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Molecules d'acides nucleiques isoles codant pour des antigenes associes au cancers, ces antigenes et leur utilisation
EP1250426A2 (fr) * 1999-12-01 2002-10-23 Genentech Inc. Polypeptides transmembranaires et secretes et les acides nucleiques codant ceux-ci
JP2001161374A (ja) * 1999-12-13 2001-06-19 Akihiro Abe ポリヌクレオチド、ポリペプチド、ガン治療薬及びワクチン
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
AU2001236782A1 (en) * 2000-02-08 2001-08-20 Agensys, Inc. 34p3d7: a tissue specific protein highly expressed in prostate cancer
AU2001259062A1 (en) * 2000-04-11 2001-10-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
US7259236B2 (en) * 2001-03-14 2007-08-21 Regents Of The University Of California RBP1L1, a novel retinoblastoma binding protein-related gene encoding an antigenic epitope and methods of using thereof
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
EP2280030A3 (fr) * 2001-04-10 2011-06-15 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
ATE415418T1 (de) * 2001-04-10 2008-12-15 Agensys Inc Nukleinsäure und entsprechendes protein mit der bezeichnung 121p2a3 zur behandlung und zum nachweis von krebs
KR100405919B1 (ko) 2001-06-05 2003-11-14 주식회사 이매진 ｐ43의 Ｎ-말단 펩타이드를 유효성분으로 하는 면역증강용 약학조성물
EP2208736A3 (fr) * 2001-12-07 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Rétrovirus endogène à régulation positive dans le cancer de la prostate
US7147855B2 (en) * 2001-12-07 2006-12-12 Juan Saus GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
US7319138B2 (en) 2002-04-18 2008-01-15 The General Hospital Corporation Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
JP2004057003A (ja) * 2002-06-03 2004-02-26 Norihiro Chano Ｒｂ１遺伝子誘導蛋白質（ｒｂ１ｃｃ１）及び遺伝子
JP2005535308A (ja) 2002-06-13 2005-11-24 カイロン コーポレイション Ｈｍｌ−２ポリペプチド発現用ベクター
EP1380644A1 (fr) * 2002-07-08 2004-01-14 Kylix B.V. Utilisation de gènes cible spécifiques de TCF pour identifier des medicaments pour le traitement du cancer, en particulier le cancer colorectal, dans lequel TCF/beta-catenin/WNT signalisation joue un rôle central
FR2849039B1 (fr) * 2002-12-24 2010-10-01 Centre Nat Rech Scient Nouvelle proteine associee aux centrosomes et ses applications
JP2006523440A (ja) 2003-04-15 2006-10-19 ゼノン ファーマスーティカルス，インコーポレイテッド 若年性ヘモクロマトーシス遺伝子（ｈｆｅ２ａ）、その発現産物および使用法
DE602005013670D1 (de) * 2004-05-21 2009-05-14 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
CA2579558A1 (fr) * 2004-09-08 2006-03-16 Ludwig Institute For Cancer Research Antigenes du cancer du testicule
US8557955B2 (en) 2006-10-17 2013-10-15 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
RU2644337C2 (ru) 2012-01-27 2018-02-08 Эббви Дойчланд Гмбх Унд Ко. Кг Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
EP2854842A4 (fr) 2012-05-25 2016-11-02 Agenus Inc Identification d'antigènes phosphopeptidiques de cmh de classe i du cancer du sein à l'aide d'une technologie shla et de stratégies d'enrichissement complémentaires
AU2013308409A1 (en) 2012-08-31 2015-03-26 University Of Birmingham Target peptides for immunotherapy and diagnostics
WO2014039675A2 (fr) 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Peptides cibles pour la thérapie et les diagnostics du cancer colorectal
US20160000893A1 (en) * 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
US10654908B2 (en) 2014-04-15 2020-05-19 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
WO2017061522A1 (fr) 2015-10-08 2017-04-13 オンコセラピー・サイエンス株式会社 Peptide dérivé de mphosph1 et vaccin le contenant
CA3060514A1 (fr) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions et procedes pour le traitement d'inflammation pulmonaire
US20210213117A1 (en) * 2018-07-26 2021-07-15 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
CN109055555B (zh) * 2018-08-27 2021-09-21 中山大学 一种肺癌早期转移诊断标志物及其试剂盒和应用
CN114606324B (zh) * 2022-05-10 2022-08-05 上海晟燃生物科技有限公司 用于辅助低剂量ct筛查肺癌的试剂盒和系统

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 14 December 1998 (1998-12-14), "Homo sapiens HSP105 alpha mRNA", XP002177945 *
DATABASE EMBL 16 August 2000 (2000-08-16), "Human endogenous retrovirus HERV-K(II)", XP002184414 *
DATABASE EMBL 2 June 1998 (1998-06-02), "Homo sapien antigen NY-CO-25 mRNA", XP002177944 *
ISHIHARA K ET AL: "Molecular cloning, expression and localization of human 105 kDa heat shock protein, hsp105.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1444, no. 1, 18 January 1999 (1999-01-18), pages 138 - 142, XP001024442 *
SCANLAN M J ET AL: "Characterization of human colon cancer antigens recognized by autologous antibodies.", INTERNATIONAL JOURNAL OF CANCER, vol. 76, no. 5, 29 May 1998 (1998-05-29), pages 652 - 658, XP002103186 *
SUGIMOTO J ET AL: "Transcriptionally active HERV-K genes: Identification, isolation, and chromosomal mapping.", GENOMICS, vol. 72, no. 2, 1 March 2001 (2001-03-01), pages 137 - 144, XP002184413 *
TÜRECI O ET AL: "Serological analysis of human tumor antigens: molecular definition and implications", MOLECULAR MEDICINE TODAY, vol. 3, no. 8, August 1997 (1997-08-01), pages 342 - 349, XP000985587 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Also Published As

Publication number Publication date
AU5047800A (en) 2000-12-18
WO2000073801A2 (fr) 2000-12-07
JP2003518364A (ja) 2003-06-10
EP1259812A2 (fr) 2002-11-27

Similar Documents

Publication Publication Date Title
WO2000073801A3 (fr) Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
WO2001053349A3 (fr) Antigenes associes au cancer du poumon a petites cellules et utilisations de ces antigenes
WO2000020587A3 (fr) Antigenes associes au cancer et leurs utilisations
TW428026B (en) Bifunctional protein, preparation and use
WO1999066025A3 (fr) NOUVELLES MOLECULES PROTEIQUES ET NUCLEOTIDIQUES MTbx ET LEURS APPLICATIONS
BR0009323A (pt) Anticorpos humanos que ligam a il-12 humana e métodos para a produção
EP1005540A4 (fr) Proteines ikk-beta, acides nucleiques et procedes
AU7599500A (en) Novel gl50 molecules and uses therefor
NZ331866A (en) Compounds for immunotherapy and immunodiagnosis of prostate cancer
WO2002086071A3 (fr) Antigenes du cancer et des testicules
WO2000052047A3 (fr) Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations
WO2002078526A3 (fr) Antigenes vis-a-vis du cancer du testicule
EP1009752A4 (fr) Nouvelles molecules de la famille des proteines de type tango-77 et utilisations de ces molecules
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
WO1998011221A3 (fr) Car, un nouveau recepteur du virus de coxsackie et d'adenovirus
WO2001000826A3 (fr) Nouvelles molecules de la famille de proteines liee a la card et utilisations de ces dernieres
WO2000046236A3 (fr) Nouvelles molecules contenant des regulateurs de signalisation de proteine g (rgs) et leurs utilisations
WO2000019988A8 (fr) NOUVELLES MOLECULES SPECIFIQUES DE Th2 ET LEURS UTILISATIONS
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
WO1998011238A3 (fr) Protease m, une nouvelle serine protease
WO2001000874A3 (fr) Antigenes associes au cancer et leurs utilisations
WO2001040271A3 (fr) Antigenes associes au cancer et utilisations correspondantes
WO2000061774A3 (fr) Proteines morphogeniques osseuses bmp
WO2000072021A3 (fr) Antigenes associes au cancer et utilisations correspondantes
WO2000008045A3 (fr) Nouvelles molecules de la famille de proteines apparentees a tango-93 et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 500870

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000932804

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000932804

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000932804

Country of ref document: EP